September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
lanosterol reverse protein aggregation in cataracts
Author Affiliations & Notes
  • Jie Zhu
    University of California San Diego, Shiley Eye Institute and Biomaterials and Tissue Engineering Center, Institute for Engineering in Medicine, La Jolla, California, United States
  • Ling zhao
    University of California San Diego, Shiley Eye Institute and Biomaterials and Tissue Engineering Center, Institute for Engineering in Medicine, La Jolla, California, United States
    Zhongshan Ophthalmic Center, Sun Yat-sen University, State Key Laboratory of Ophthalmology, Guangzhou, China
  • Xiangjun Chen
    Tsinghua University, State Key Laboratory of Membrane Biology, School of Life Sciences, Beijing, China
  • Sha Wang
    University of California San Diego, Shiley Eye Institute and Biomaterials and Tissue Engineering Center, Institute for Engineering in Medicine, La Jolla, California, United States
    Tsinghua University, State Key Laboratory of Membrane Biology, School of Life Sciences, Beijing, China
  • Huimin Cai
    Molecular Medicine Research Center, West China Hospital, Sichuan University, Chengdu, China
    Guangzhou KangRui Biological Pharmaceutical Technology Company Ltd., Guangzhou, China
  • Rui Hou
    Guangzhou KangRui Biological Pharmaceutical Technology Company Ltd., Guangzhou, China
  • Wenqiu Wang
    University of California San Diego, Shiley Eye Institute and Biomaterials and Tissue Engineering Center, Institute for Engineering in Medicine, La Jolla, California, United States
  • Tingshuai Jiang
    University of California San Diego, Shiley Eye Institute and Biomaterials and Tissue Engineering Center, Institute for Engineering in Medicine, La Jolla, California, United States
  • Yong-Bin Yan
    Tsinghua University, State Key Laboratory of Membrane Biology, School of Life Sciences, Beijing, China
  • Kang Zhang
    University of California San Diego, Shiley Eye Institute and Biomaterials and Tissue Engineering Center, Institute for Engineering in Medicine, La Jolla, California, United States
    Molecular Medicine Research Center, West China Hospital, Sichuan University, Chengdu, China
  • Footnotes
    Commercial Relationships   Jie Zhu, None; Ling zhao, None; Xiangjun Chen, None; Sha Wang, None; Huimin Cai, None; Rui Hou, None; Wenqiu Wang, None; Tingshuai Jiang, None; Yong-Bin Yan, None; Kang Zhang, None
  • Footnotes
    Support  973 Project (2015CB94600, 2012CB917304), 863 Program (2014AA021604), NSFC (31327901), State Key Laboratory of Ophthalmology, and State Key Laboratory of Membrane Biology
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 2497. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Jie Zhu, Ling zhao, Xiangjun Chen, Sha Wang, Huimin Cai, Rui Hou, Wenqiu Wang, Tingshuai Jiang, Yong-Bin Yan, Kang Zhang; lanosterol reverse protein aggregation in cataracts. Invest. Ophthalmol. Vis. Sci. 2016;57(12):2497.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Cataracts are the most common cause of blindness worldwide, and currently the only treatment is surgical removal of cataractous lenses. The precise mechanisms by which lens proteins maintain lens transparency are largely unknown. Lanosterol is an amphipathic molecule enriched in the lens. It is synthesized by lanosterol synthase (LSS) in a key cyclization reaction of a cholesterol synthesis pathway. We investigated a role of LSS mutations in congenital cataracts in humans and in animal models.

Methods : Exome capture were performed to screen for mutations in the LSS gene in congenital cataracts. LSS mutant knockout mice were generated by CRISPR-Cas technology and their phenotypes characterized.

Results : We identified two distinct homozygous LSS missense mutations (W581R and G588S) in two families with congenital cataracts. Engineered expression of wild-type (WT), but not mutant LSS, prevents intracellular protein aggregation of various cataract-causing mutant crystallins. Treatment by lanosterol, but not cholesterol, significantly decreased pre-formed protein aggregates both in vitro and in cell transfection experiments. We further showed that lanosterol treatment could reduce cataract and increase transparency in dissected rabbit cataract lenses in vitro and cataract in vivo in dogs. The critical role of lanosterol in cataract formation is supported by the observation that LSS missense mutation mouse recapitulates the human cataract disease phenotype.

Conclusions : Our study identifies lanosterol as a key molecule in the prevention of lens protein aggregation and points to a novel strategy for cataract prevention and treatment.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×